for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

T2 Biosystems Inc

TTOO.OQ

Latest Trade

1.26USD

Change

0.00(0.00%)

Volume

244,762

Today's Range

1.25

 - 

1.37

52 Week Range

0.48

 - 

3.79

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.26
Open
1.29
Volume
244,762
3M AVG Volume
168.25
Today's High
1.37
Today's Low
1.25
52 Week High
3.79
52 Week Low
0.48
Shares Out (MIL)
148.49
Market Cap (MIL)
187.10
Forward P/E
-4.60
Dividend (Yield %)
--

Next Event

Q1 2021 T2 Biosystems Inc Earnings Release

Latest Developments

More

T2 Biosystems Reports Q4 Loss Per Share of $0.07

T2 Biosystems Inc Says Entered Into Amendment No.6 To Term Loan Agreement With CRG Servicing Llc On Jan. 25

T2 Biosystems Sees Q4 2020 Revenue $7.8 million

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About T2 Biosystems Inc

T2 Biosystems, Inc. is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company's T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL). The Company's initial development efforts target sepsis, hemostasis and Lyme disease. T2MR is a miniaturized, magnetic resonance-based approach that measures how water molecules react in the presence of magnetic fields. Its platform detects a range of targets, including molecular targets, such as deoxyribonucleic acid (DNA), immunodiagnostics, such as proteins, and a range of hemostasis measurements. The Company offers T2Dx Instrument (T2Dx) and the T2Candida Panel.

Industry

Medical Equipment & Supplies

Contact Info

101 Hartwell Ave

LEXINGTON, MA

02421-3125

United States

+1.781.4571200

http://www.t2biosystems.com/

Executive Leadership

John McDonough

Non-Executive Chairman of the Board

John J. Sperzel

President, Chief Executive Officer, Director

John M. Sprague

Chief Financial Officer

Alec Barclay

Chief Operating Officer

Thomas J. Lowery

Chief Scientific Officer

Key Stats

1.60 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-1.260

2019

-1.300

2020

-0.390

2021(E)

-0.294
Price To Earnings (TTM)
--
Price To Sales (TTM)
10.32
Price To Book (MRQ)
21.38
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
518.39
LT Debt To Equity (MRQ)
518.39
Return on Investment (TTM)
-251.66
Return on Equity (TTM)
-87.01

Latest News

Latest News

BRIEF-T2 Biosystems Sees Q2 2020 Revenue $2.4 Million To $2.6 Million

* T2 BIOSYSTEMS ANNOUNCES PRELIMINARY SECOND QUARTER 2020 FINANCIAL RESULTS

BRIEF-T2 Biosystems Announces U.S. Launch Of COVID-19 Diagnostic Test

* T2 BIOSYSTEMS ANNOUNCES U.S. LAUNCH OF COVID-19 DIAGNOSTIC TEST Source text for Eikon: Further company coverage:

BRIEF-T2 Biosystems Says Regained Compliance With Nasdaq Listing Rule

* T2 BIOSYSTEMS - RECEIVED WRITTEN NOTICE FROM NASDAQ NOTIFYING CO HAD REGAINED COMPLIANCE WITH NASDAQ LISTING RULE Source: (https://bit.ly/2N5fXEf) Further company coverage:

BRIEF-T2 Biosystems Regains Compliance With Nasdaq Listing Requirements

* T2 BIOSYSTEMS REGAINS COMPLIANCE WITH NASDAQ LISTING REQUIREMENTS Source text for Eikon: Further company coverage:

BRIEF-T2 Biosystems Announces Changes To Board Of Directors

* T2 BIOSYSTEMS ANNOUNCES CHANGES TO BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-T2 Biosystems Expects Demand For T2SARS-COV-2 Test Upon Being Made Commercially Available For Clinical Use

* T2 BIOSYSTEMS - ANTICIPATES DEMAND FOR THE T2SARS-COV-2 TEST UPON BEING MADE COMMERCIALLY AVAILABLE FOR CLINICAL USE

BRIEF-T2 Biosystems Q1 Loss Per Share $0.22

* T2 BIOSYSTEMS ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS

BRIEF-T2 Biosystems Suspends Full Year 2020 Financial And Operational Guidance

* T2 BIOSYSTEMS ANNOUNCES PRELIMINARY FIRST QUARTER 2020 FINANCIAL RESULTS

BRIEF-T2 Biosystems Announces Worldwide Licensing Agreement Of Covid-19 Assay

* T2 BIOSYSTEMS ANNOUNCES WORLDWIDE LICENSING AGREEMENT OF COVID-19, NOVEL CORONAVIRUS ASSAY FROM HACKENSACK MERIDIAN HEALTH’S CENTER FOR DISCOVERY AND INNOVATION

BRIEF-T2 Biosystems Receives Multiyear Innovative Technology Contract From Vizient

* T2 BIOSYSTEMS RECEIVES MULTIYEAR INNOVATIVE TECHNOLOGY CONTRACT FROM VIZIENT, INC. Source text for Eikon: Further company coverage:

BRIEF-T2 Biosystems Says Entered Into Amendment No. 1 To Equity Distribution Deal With Canaccord Genuity

* T2 BIOSYSTEMS INC - ON MAR 9, CO ENTERED INTO AMENDMENT NO. 1 TO EQUITY DISTRIBUTION AGREEMENT WITH CANACCORD GENUITY LLC

BRIEF-T2 Biosystems Reports Q4 Loss Per Share $0.30

* T2 BIOSYSTEMS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

BRIEF-T2 Biosystems Amends Oct. 10, 2014 Supply Agreement With SMC Ltd

* T2 BIOSYSTEMS SAYS ON MAY 16, CO & SMC LTD ENTERED INTO A THIRD AMENDMENT AMENDING CERTAIN SUPPLY AGREEMENT DATED AS OF OCT. 10, 2014 - SEC FILING

BRIEF-T2 Biosystems Reports Q1 Loss Per Share Of $0.36

* T2 BIOSYSTEMS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up